logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9556191 B1

PDFFull Text
Date of Patent:
Jan. 31, 2017

Filed:

Apr. 28, 2014

Aminoquinazoline derivatives and their salts and methods of use thereof

Applicant:

Sunshine Lake Pharma Co., Ltd, Dongguan, Guangdong, CN;

Inventors:

Yingjun Zhang, Dongguan, CN;

Bing Liu, Dongguan, CN;

Jinlei Liu, Dongguan, CN;

Jiancun Zhang, Dongguan, CN;

Changchung Cheng, Dongguan, CN;

Assignee:

SUNSHINE LAKE PHARMA CO., LTD., Dongguan, Guangdong, CN;

Attorneys:

Kam W. Law

Squire Patton Boggs (US) LLP

Primary Examiner:

Jeffrey H Murray

Int. Cl.
CPC ...
A01N 43/54 (2006.01); A61K 31/517 (2006.01); C07D 239/72 (2006.01); C07D 491/056 (2006.01); A61K 31/5415 (2006.01); A61K 31/553 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 403/12 (2006.01); C07D 401/12 (2006.01); C07D 495/04 (2006.01); C07D 497/04 (2006.01); C07D 498/04 (2006.01); C07D 519/00 (2006.01); A61K 31/196 (2006.01); A61K 31/198 (2006.01); A61K 31/255 (2006.01); A61K 31/475 (2006.01); A61K 31/675 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/4545 (2006.01); A61K 31/5377 (2006.01); A61K 31/538 (2006.01); A61K 31/5383 (2006.01); A61K 31/573 (2006.01); A61K 31/7008 (2006.01); A61K 31/704 (2006.01); A61K 33/24 (2006.01); A61K 38/12 (2006.01); A61K 38/21 (2006.01); A61K 39/395 (2006.01); C07D 491/044 (2006.01); C07D 491/048 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07D 491/056 (2013.01); A61K 31/196 (2013.01); A61K 31/198 (2013.01); A61K 31/255 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/4545 (2013.01); A61K 31/475 (2013.01); A61K 31/517 (2013.01); A61K 31/538 (2013.01); A61K 31/5377 (2013.01); A61K 31/5383 (2013.01); A61K 31/5415 (2013.01); A61K 31/553 (2013.01); A61K 31/573 (2013.01); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 31/7008 (2013.01); A61K 33/24 (2013.01); A61K 38/12 (2013.01); A61K 38/212 (2013.01); A61K 39/39558 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07D 491/044 (2013.01); C07D 491/048 (2013.01); C07D 495/04 (2013.01); C07D 497/04 (2013.01); C07D 498/04 (2013.01); C07D 519/00 (2013.01); A61K 2039/505 (2013.01);
Abstract

Provided herein are aminoquinazoline compounds, salts and uses thereof. The compounds have Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Also provided herein are pharmaceutical compositions containing the compounds disclosed herein, and uses of the compounds or the compositions for preventing, managing, treating or lessening the severity of a proliferative disorder in a patient and for modulating the protein tyrosine kinase activity.

Find Patent Forward Citations

Loading…